Opiates (OPI) Rapid Test

Opiates are natural opioid substances derived from the opium poppy plant. Common examples include morphine and codeine. In drug screening, OPI usually refers to an opiate screening marker used to detect selected opiate compounds or related metabolites in urine. A 2000 ng/mL opiate test is often calibrated around morphine. Because different test brands and panel designs may vary, users should always check the product insert, regulatory documentation, and cut-off table for exact compounds and cross-reactivity profile.

• The OPI Rapid Test is important because opiates may be used medically, misused, or encountered in drug abuse screening contexts.
• The LARKSOIS Pharma Opiates OPI Rapid Test may be used in workplace and pre-employment drug screening, rehabilitation centers, clinical toxicology screening, hospitals, diagnostic laboratories, pain-management compliance support, forensic screening, and international diagnostic distribution.
• The OPI urine rapid test helps professional users screen urine samples quickly and decide whether further laboratory confirmation is required.

The Opiates (OPI) Rapid Test by LARKSOIS Pharma may be used in professional diagnostic and institutional screening environments.

Applications

• Workplace and pre-employment drug screening
• Rehabilitation and de-addiction centers
• Clinical toxicology screening
• Hospitals and diagnostic laboratories
• Pain-management compliance support
• Forensic and legal screening support
• International diagnostic distribution
• Laboratory and institutional drug monitoring workflows

• The Opiates OPI Rapid Test generally works through a rapid immunoassay format. A urine specimen is collected in a clean container, the test is performed according to the product insert, and the visual result is interpreted within the stated reading time.
• The test is designed to detect opiate-related markers at or above the 2000 ng/mL cut-off level.
• For official decisions, non-negative screening results should be confirmed by a suitable laboratory method because positive screening results may require follow-up testing to confirm the result.

• Many users confuse OPI, opioid, and oxycodone, but they are not identical terms.
• OPI usually refers to an opiate marker on a drug test.
• Opiates usually refer to natural opioid compounds such as morphine and codeine.
• Opioids is a broader category that includes opiates plus synthetic and semi-synthetic drugs.
• Oxycodone is a semi-synthetic opioid and is often tested separately as OXY, because standard OPI 2000 tests may not detect oxycodone strongly enough at normal opiate cut-offs.

The Opiates (OPI) Rapid Test uses a rapid urine screening method for qualitative detection of opiate-related markers. It is designed to provide a preliminary screening result at the stated 2000 ng/mL cut-off.

Benefits

• Urine-based opiate screening
• 2000 ng/mL cut-off for professional testing requirements
• Fast qualitative drug of abuse screening
• Simple rapid test method
• Suitable for laboratories and field screening programs
• Useful for workplace, rehabilitation, clinical, and forensic testing
• Supports international diagnostic supply
• Helps identify samples that may need confirmatory testing

The Opiates (OPI) Rapid Test is designed for urine specimens. Urine is widely used in drug screening because it is practical, non-invasive, and suitable for professional toxicology screening workflows.

Guidance

• Use urine specimens only
• Use a clean urine specimen container
• Follow the product insert exactly
• Read results within the stated time window
• Do not reuse the test device
• Record test details correctly
• Treat all urine samples as potentially biohazardous
• Send non-negative or disputed results for confirmation when required

Note

A rapid screening result should be considered preliminary unless confirmed by a validated laboratory method where required.

The Opiates (OPI) Rapid Test by LARKSOIS Pharma has a stated cut-off of 2000 ng/mL. This means the test is designed to screen urine specimens for opiate-related markers at or above the validated threshold. LARKSOIS Pharma should mention the exact performance details according to the final product insert, technical file, and regulatory documentation.

The OPI urine test is a screening product, not a final diagnostic result. A negative result does not always mean no opiate is present; the level may be below the test cut-off or outside the detection window. A non-negative result does not prove impairment, addiction, misuse, or exact timing of drug use.

Instructions

• A positive result is preliminary only
• A negative result does not always rule out exposure
• Drug levels may be below the cut-off concentration
• Specimen quality may affect the result
• Medication or metabolite cross-reactivity may occur
• Testing method differences may affect interpretation
• Confirmatory testing is recommended for important results

Instructions

• Urine-based opiate screening
• 2000 ng/mL cut-off for professional testing requirements
• Fast qualitative drug of abuse screening
• Simple rapid test method
• Suitable for laboratories and field screening programs
• Useful for workplace, rehabilitation, clinical, and forensic testing
• Supports international diagnostic supply
• Helps identify samples that may need confirmatory testing

Note

The Opiates OPI Rapid Test by LARKSOIS Pharma is developed for professional users who need a practical, easy-to-use, and internationally suitable opiate screening solution.

Steps

• Bring the test device and urine specimen to the recommended testing condition
• Open the sealed pouch only when ready to test
• Collect urine using a clean sample collection procedure
• Apply the urine specimen according to the product insert
• Wait for the test reaction to complete within the instructed time
• Read the result within the approved interpretation window
• Dispose of used materials according to laboratory safety rules

Note

The exact procedure must follow the official LARKSOIS Pharma product insert supplied with the Opiates (OPI) Rapid Test.

Positive

A positive or non-negative result suggests that opiate-related markers may be present in the urine specimen at or above the stated cut-off. Positive results are preliminary and should be confirmed using a recognized laboratory method where required.

Negative

A negative result suggests that opiate-related markers were not detected or were below the cut-off at the time of testing. A negative result does not always rule out exposure if sample quality, collection timing, or the detection window affects the result.

Invalid

If the valid control indicator does not appear, the test is invalid. The test should be repeated with a new device and fresh urine specimen according to the product insert.

Instructions

• Store according to the product label and package insert
• Keep the test device sealed until use
• Protect from moisture and direct sunlight
• Avoid using expired or damaged tests
• Use a clean urine specimen container
• Read results within the stated time window
• Do not reuse the test device

Instructions

• For professional screening use only
• Use urine specimen only as directed
• Do not reuse the test device
• Follow the product insert carefully
• Handle all urine specimens as potentially infectious material
• Do not interpret results after the recommended reading time
• Confirm presumptive positive results with laboratory testing
• Follow applicable drug testing laws and reporting requirements

LARKSOIS Pharma provides international-quality pharmaceutical and diagnostic products for global healthcare and screening markets. The Opiates OPI Rapid Test is suitable for distributors, laboratories, hospitals, rehabilitation centers, workplace testing providers, and toxicology screening programs.

Advantages

• International diagnostic product focus
• Reliable rapid testing solutions
• Suitable for laboratories and healthcare suppliers
• Distributor-friendly product format
• Supports drug of abuse screening programs
• Designed for practical urine screening workflows
• Quality-focused standards under LARKSOIS Pharma